A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

NCT03250273 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Cholangiocarcinoma
Cholangiocarcinoma
Pancreatic Cancer
Metastatic Pancreatic Cancer
Unresectable Pancreatic Cancer
Unresectable Cholangiocarcinoma

Interventions

DRUG: Entinostat
DRUG: Nivolumab
DRUG: Entinostat
DRUG: Nivolumab

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]
[object Object]
[object Object]